Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 5;3(1):e0001316.
doi: 10.1371/journal.pgph.0001316. eCollection 2023.

Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali

Fara Wagbo Temessadouno  1   2 , Jean Gilbert Ndong  3 , Etienne Gignoux  2 , Yves Coppieters  4 , Alhassane Ba  5 , Youssouf Diam Sidibe  5 , Aminata Daou  6 , Nada Malou  6 , Idrissa Compaore  3 , Tidiani Fane  3 , Erica Simons  2 , Francisco Luquero  2 , Clair Mills  7 , Komla Mawunya Vuti  6 , Marie Hortense Nkokolo Massamba  1 , Sonia Guiramand  7
Affiliations

Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali

Fara Wagbo Temessadouno et al. PLOS Glob Public Health. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus associated with coronavirus disease (COVID-19). At the time of the study, little data on the level of exposure of the population in Koutiala district in Mali to SARS-CoV-2 was available. Although blood donors are not representative of the general population, a COVID-19 seroprevalence estimate in this population was intended to assess the extent of community transmission, serve as a health alert system, and help guide the public health response. We measured seroprevalence of anti-SARS-CoV-2 antibodies using NG-Biotech SARS-Cov-2 RDT and ECLIA test between January and June 2020. This is a cross-sectional study of volunteer blood donors aged 18 to 60 years, independent of any previous COVID-19 disease. A stratified analysis of seroprevalence by month of sample collection and a comparison of the results of the NG-Biotech SARS-Cov-2 RDT with those of the ECLIA test was performed. The overall prevalence of antibodies to SARS-Cov-2 virus assessed by the NG-Biotech SARS-Cov-2 RDT was 24.6% (95% CI 21.8-27.4) and by the ECLIA test was 70.2 (95% CI 64.9-75.5). Both estimates remained relatively stable over the study period. We observed SARS-CoV-2 exposure much higher than indicated by case-based surveillance. The national surveillance system, as it was, was not able to detect variations in incidence, and as such, we do not recommend it as an alert system. However, the discrepancy between the results of the rapid test and the ECLIA test shows that further research is required to assess the validity of these test before a more solid conclusion can be drawn it their use in surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Seroprevalence of anti-sars-cov-2 antibodies among blood donors participants’ flow chart.
Fig 2
Fig 2. Comparative evolution of prevalence seroprevalence survey versus national surveillance systems, Koutiala, Mali, December 2020 to June 2021.
Longitudinal monitoring at national level of the proportion of positive COVID-19 PCR tests, Mali national surveillance system and seroprevalence survey results for the same period.
See this image and copyright information in PMC

References

    1. Johns Hopkins Coronavirus Resource Center. COVID-19 Map [Internet]. Available from: https://coronavirus.jhu.edu/map.html
    1. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al.. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020. Dec 1;180(12):1576. doi: 10.1001/jamainternmed.2020.4130 - DOI - PubMed
    1. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al.. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [Internet]. In Review; 2020. Apr [cited 2022 May 25]. Available from: https://www.researchsquare.com/article/rs-25862/v1
    1. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al.. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfus [Internet]. 2021. Apr 28 [cited 2022 May 25]; Available from: doi: 10.2450/2021.0324-20 - DOI - PMC - PubMed
    1. Thompson C. et al.. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors—a pilot study of the value of serology to determine population exposure. [Internet]. 2020. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/ppmedrxiv-20060467?lang=en

LinkOut - more resources